Company intelligence / Profile preview

辉诺生物医药科技

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Huinno Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative antiviral therapies. The company focuses on addressing significant unmet medical needs in infectious diseases, including COVID-19, influenza, and chronic hepatitis B. Its lead programs include HN01, a 3CL protease inhibitor for COVID-19, and HN06, a cap-dependent endonuclease inhibitor for influenza. Huinno Biotech leverages its deep expertise in medicinal chemistry and virology to develop highly potent and selective small molecule drugs. The company is backed by prominent venture capital firms such as Matrix Partners China and Sequoia China.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 辉诺生物医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 辉诺生物医药科技.

Explore the full profile